Production of SARS-CoV-2 virus-like particles as a vaccine candidate in stable cell lines through inducible E and M protein expression.

ABSTRACT: Virus-like particles (VLPs) offer potentially high-immunogenicity/low-cost vaccine platforms. SARS-CoV-2 VLPs production is achieved via transient transfection of genes encoding viral structural proteins, but is costly and difficult to scale up. To address this problem, stable VLPs-producing cell lines are desirable. In this study, we achieved efficient VLPs production by HEK293T cells after transient transfection of four plasmids containing the S, M, N, and E genes with optimized codons. Moreover, spike-specific IgG antibodies were elicited in mice, though no significant neutralizing activity was detected at the tested time points. Transmission electron microscopy (TEM) revealed that the VLPs diameters were approximately 120 nm. However, overexpression of E or M proteins was toxic to the

SUBMITTER: Liu Y 

PROVIDER: S-EPMC12302831 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature